C10BA

5 ××× × 2024 02:05:47Â Â +	×ª××¨××Â ××©×× ××××× ×××¤××× ××××× ×××ª×¨ ×××§× ××.
Chemical subgroupÂ Â + , Lipid modifying agents, combinations - C10BÂ Â +	×ª×ªÂ ×§××××¨××Â ×©×××× ×××¤××× ××××× ×××ª×¨ ×××§× ××.

××¡×ª×¨×ª ×××¤××× ×× ×××§×©×¨×× ××××Â

×§××××¨×××ª

××××× 10 ×"×/10 ×"× - Atozet10 mg/10 mgÂ + , ××××× 10 ×"×/20 ×"× - Atozet10 mg/20 mgÂ + , ××××× 10 ×"×/40 ×"× - Atozet10 mg/40 mgÂ + , ××××× 10 ×"×/80 ×"× - Atozet10 mg/80 mgÂ + , ××××××¨ ××¡.×§××. 10/10 ×"× - Ezator s.k. 10/10 mgÂ + , ××××××¨ ××¡.×§××. 20/10 ×"× - Ezator s.k. 10/20 mgÂ + , ××××××¨ ××¡.×§××. 40/10 ×"× - Ezator s.k. 10/40 mgÂ + , ××××××¨ ××¡.×§××. 80/10 ×"× - Ezator s.k. 10/80 mgÂ + , ×××××××¨×× 10 ×"×/10 ×"× - Ezeatorva 10 mg/10 mgÂ + , ×××××××¨×× 10 ×"×/20 ×"× - Ezeatorva 10 mg/20 mgÂ + , ×××××××¨×× 10 ×"×/40 ×"× - Ezeatorva 10 mg/40 mgÂ + , ×××××××¨×× 10 ×"×/80 ×"× - Ezeatorva 10 mg/80 mgÂ + , ×¨××¡×××× ××¡.×§××. 10/10 ×"× - Rosetemib s.k. 10/10 mgÂ + , ×¨××¡×××× ××¡.×§××. 20/10 ×"× - Rosetemib s.k. 20/10 mgÂ + , ×¨××¡×××× ××¡.×§××. 40/10 ×"× - Rosetemib s.k. 40/10 mgÂ + , ×¨××¡×××× ××¡.×§××. 5/10 ×"× - Rosetemib s.k. 5/10 mgÂ + , ×¨××× ×××¢ 10 ×"× / 10 ×"× - Rozet teva 10 mg/10 mgÂ + , ×¨××× ×××¢ 20 ×"× / 10 ×"× - Rozet teva 20 mg/10 mgÂ + , ×¨××× ×××¢ 40 ×"× / 10 ×"× - Rozet teva 40 mg/10 mgÂ + , ×¨××× ×××¢ 5 ×"×/10 ×"× - Rozet teva 5 mg/10 mgÂ + â¦

××£ ××¤× ××

C10BAÂ + , HMG CoA reductase inhibitors in combination with other lipid modifying agents - C10BAÂ + , ×§××××¨××:HMG CoA reductase inhibitors in combination with other lipid modifying agents - C10BAÂ +

Â

Â